Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Reuters

2025/09/05

Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China

Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565656652"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565656652\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565656652?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565656652","market":"fut","top_or_hot":-1,"title":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-05 21:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology <a href=\"https://laohu8.com/S/CSCO\">$(CSCO)$</a> Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable <a href=\"https://laohu8.com/S/MSS\">$(MSS)$</a> colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a>. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLbxCv5:1","article_id":"2565656652","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565656652","pubTimestamp":1757080526,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire  on September 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","ADAG":"天演药业","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Adagene Inc.在2025年中国CSCO会议上宣布ADG126与帕博利珠单抗联合用药的良好结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAG":0.9,"NDAQ":0.9},"content_text":"Adagene Inc. Announces Promising Results for ADG126 in Combination with Pembrolizumab at 2025 CSCO Meeting in China\n    \n\n        Adagene Inc. has announced that its investigational therapy, ADG126, will be highlighted in two oral presentations at the upcoming Chinese Society of Clinical Oncology $(CSCO)$ Meeting, scheduled to take place from September 10-14, 2025, in Jinan, China. The presentations will focus on updated results from the ADG126-P001 Phase 1b/2 study, which evaluated the combination of ADG126 and pembrolizumab in advanced microsatellite stable $(MSS)$ colorectal cancer $(CRC)$. The study demonstrated that ADG126, a masked anti-CTLA-4 therapy, achieved an objective response rate of approximately 30% and over 80% disease control in patients with refractory/resistant MSS CRC without liver metastasis. The safety profile of ADG126 allows for higher, more frequent dosing in combination with pembrolizumab, showing potential for long-term survival benefits. These results will be presented by Dr. Xu Ruihua and Dr. Heinz-Josef Lenz during the CSCO meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9524112-en) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}